• en English
    af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
       

All fields are required.

Close Appointment form

Improving patient outcomes with innovative drug therapies.

Managing Kidney Disease

Rockwell Medical is a biopharmaceutical company dedicated to improving outcomes for anemia patients, with a focus on end-stage renal disease (ESRD). Rockwell Medical is a global manufacturer of both pharmaceutical products and high-quality hemodialysis concentrates and dialysates with a goal to help patients on dialysis.

Bio-Pharma Development Program

As part of the long-term growth strategy, the company is establishing global partnerships and licensing opportunities for world-wide distribution and sale of all its therapies.

Improving Patient Outcomes

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients for intended safe and effective delivery.

Investor Center
Investor Center

Rockwell Medical’s common shares are traded on NASDAQ under the symbol RMTI. More ››

Latest News

3/31/20

Rockwell Medical, Inc. Appoints Pharmaceutical Industry Leader Robert S. Radie to Board of Directors

3/27/20

Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients

3/20/20

Rockwell Medical, Inc. Confirms Medical Resource Acquisition Group’s Director Nominations Are Invalid

3/17/20

Rockwell Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC

3/12/20

Rockwell Medical, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results

3/11/20

Rockwell Medical Determines Medical Resource Acquisition Group’s Director Nominations Are Invalid

3/10/20

Rockwell Medical Acknowledges Receipt of Communications from Medical Resource Acquisition Group

3/4/20

Rockwell Medical, Inc. to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

2/27/20

Rockwell Medical, Inc. Provides Business Update

2/6/20

Rockwell Medical, Inc. to Present at 2020 BIO CEO & Investor Conference

2/4/20

Rockwell Medical Announces Pricing of $7.5 Million Public Offering of Common Stock

2/3/20

Rockwell Medical Announces Proposed Public Offering of Common Stock

1/14/20

Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in India

1/9/20

Rockwell Medical, Inc. Appoints Russell H. Ellison, MD, MSc, to Board of Directors

1/8/20

Rockwell Medical, Inc. to Present at Biotech Showcase 2020

11/21/19

Rockwell Medical, Inc. to Present at 31st Annual Piper Jaffray Healthcare Conference

11/20/19

Rockwell Medical, Inc. Expands Medical Capabilities

11/11/19

Rockwell Medical, Inc. Reports Third Quarter 2019 Financial Results

11/7/19

Rockwell Medical, Inc. to Sponsor Triferic® Exhibitor Spotlight Presentation at American Society of Nephrology Conference

11/4/19

Rockwell Medical, Inc. to Discuss Third Quarter 2019 Financial Results on November 11, 2019

10/31/19

Rockwell Medical, Inc. Appoints John P. McLaughlin Chairman of the Board of Directors

10/24/19

Rockwell Medical, Inc. Provides Business Update

9/24/19

Rockwell Medical, Inc. 2019 Cantor Global Healthcare Presentation

9/5/19

Rockwell Medical, Inc. Appoints Industry Veteran John P. McLaughlin to Board of Directors

8/28/19

Rockwell Medical, Inc. to Present at Upcoming September Conferences

8/8/19

Rockwell Medical, Inc. Reports Second Quarter 2019 Financial Results

8/8/19

Rockwell Medical, Inc. Announces Completion of Two Clinical Pharmacology Studies of TRIFERIC® in China

5/29/19

Rockwell Medical, Inc. Announces Submission of New Drug Application for I.V. Triferic®

5/9/19

Rockwell Medical, Inc. Reports First Quarter 2019 Financial Results

5/6/19

Rockwell Medical, Inc. Commences Commercial Sales of Dialysate Triferic® in the U.S.

5/2/19

Rockwell Medical, Inc. to Discuss First Quarter 2019 Financial Results on May 9, 2019

5/1/19

CMS Issues Preliminary Recommendation to Establish a New J-Code for Triferic® Powder Packet

4/3/19

Rockwell Medical, Inc. to Present at H.C Wainwright Global Life Sciences Conference

3/18/19

Rockwell Medical Announces I.V. Triferic® and Peritoneal Dialysis Study Abstracts Selected as Best-in-Category at the Annual Dialysis Conference

3/14/19

Rockwell Medical, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results

3/6/19

Rockwell Medical, Inc. to Discuss Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019

See All News >

print page

© 2020 Rockwell Medical